Pdia4 regulates β-cell pathogenesis in diabetes: molecular mechanism and targeted therapy

Area of Science:

• Endocrinology
• Metabolic Diseases
• Cell Biology

Background:

• Diabetes mellitus is characterized by beta-cell loss and dysfunction.
• Beta-cell preservation is a key strategy for diabetes treatment and reversal.
• The role of Pdia4 in beta-cell pathogenesis remains largely unexplored.

Purpose of the Study:

• To investigate the role of Pdia4 in beta-cell function and diabetes.
• To identify Pdia4 as a potential therapeutic target for diabetes.

Main Methods:

• Examined Pdia4 expression in pancreatic beta cells and blood under diabetic conditions.
• Utilized Pdia4 knockout and overexpression mouse models.
• Assessed metabolic parameters, including blood glucose, HbA1c, and insulin secretion.
• Investigated the molecular mechanisms of Pdia4 action on reactive oxygen species (ROS) production.
• Tested the efficacy of a Pdia4 inhibitor (GHTT) in a mouse model of diabetes.

Main Results:

• Pdia4 is primarily expressed in beta cells and upregulated by excess nutrients.
• Pdia4 ablation ameliorated diabetes, reducing islet destruction, blood glucose, HbA1c, and ROS, while increasing insulin secretion.
• Pdia4 overexpression exacerbated diabetic phenotypes.
• Pdia4 promotes beta-cell death, dysfunction, and ROS production via Ndufs3 and p22phox pathways.
• The Pdia4 inhibitor GHTT suppressed diabetic development in mice.

Conclusions:

• Pdia4 is a critical regulator of beta-cell pathogenesis and diabetes.
• Targeting Pdia4 represents a promising therapeutic strategy for diabetes treatment and reversal.
• Pdia4 serves as a potential diagnostic marker for diabetes.